Juno Therapeutics started at buy by Wells Fargo
Equities researchers at Wells Fargo & Company assumed coverage on shares of Juno Therapeutics Inc (NDAQ:JUNO) in a research note issued to investors on Wednesday. The firm set an “outperform” rating on the stock.
Advertisements
Leave a Comment